High Purity 99% Cancer Treatment Afatinib CAS 439081-18-2 Afatinib

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A16
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Afatinib
• Appearance: White Powder
• Assay: 99%
• CAS: 439081-18-2
• OEM: Available
• Sample: Available
• Suitable: Adult
• Function: Oncology Treatment
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

Product Name	Afatinib
CAS NO.	439081-18-2
Purity	99%
Melting point	98-110 C
Appearance and shape	White powder

Afatinib (BIBW 2992) is the second-generation potent and irreversible dual inhibitor of the epidermal receptor (EGFR) and human epidermal receptor 2 (HER2) tyrosine kinase, developed by Boehringer Ingelheim, Germany. It is capable of irreversibly inhibiting the activity of the tyrosine kinase by undergoing the Michael reaction with the thiol group of cysteine at position 797 of the EGFR. 

1. Oncology Treatment: Afatinib powder is primarily used in the treatment of certain types of non-small cell lung cancer (NSCLC) that have specific genetic mutations, such as those with EGFR exon 19 deletions or exon 21 L858R substitution mutations.

2. Targeted Therapy: As a targeted therapy, it selectively inhibits multiple members of the HER family, including EGFR, HER2, HER3, and HER4, thereby blocking tumor growth signals and promoting cell death in cancer cells.

3. Combination Therapy: Afatinib may also be used in combination with other chemotherapeutics or targeted agents to enhance treatment outcomes in select patient populations.

1. Inhibition of HER Family Signaling: By blocking the activation of HER family receptors, afatinib disrupts the signaling pathways that promote cancer cell growth, proliferation, survival, and migration.

2. Induction of Apoptosis: By inhibiting these crucial signaling pathways, afatinib triggers programmed cell death (apoptosis) in cancer cells, leading to tumor regression.

3. Angiogenesis Inhibition: It may also indirectly inhibit angiogenesis, the formation of new blood vessels that supply tumors with nutrients and oxygen, further starving and inhibiting tumor.

4. Selective Toxicity: Afatinib exhibits selectivity towards cancer cells with HER family mutations, minimizing toxicity to healthy cells, though side effects can still occur.

5. Improvement of Survival Outcomes: In clinical trials, afatinib has demonstrated the ability to improve progression-free survival and overall survival in patients with advanced NSCLC who harbor specific EGFR mutations.